Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Interest Expenses (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Interest Expenses data on record, last reported at $6.3 million in Q3 2025.

  • For Q3 2025, Interest Expenses fell 6.18% year-over-year to $6.3 million; the TTM value through Dec 2025 reached $12.6 million, down 58.57%, while the annual FY2024 figure was $30.3 million, 11.73% up from the prior year.
  • Interest Expenses reached $6.3 million in Q3 2025 per AMPH's latest filing, roughly flat from $6.3 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $13.7 million in Q3 2023 and bottomed at $86000.0 in Q2 2021.
  • Average Interest Expenses over 5 years is $4.0 million, with a median of $2.1 million recorded in 2022.
  • Peak YoY movement for Interest Expenses: skyrocketed 2320.85% in 2023, then tumbled 51.12% in 2024.
  • A 5-year view of Interest Expenses shows it stood at $168000.0 in 2021, then skyrocketed by 214.29% to $528000.0 in 2022, then soared by 1690.91% to $9.5 million in 2023, then plummeted by 32.05% to $6.4 million in 2024, then decreased by 2.19% to $6.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $6.3 million in Q3 2025, $6.3 million in Q1 2025, and $6.4 million in Q4 2024.